Milestone Scientific (NYSE:MLSS) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of Milestone Scientific (NYSE:MLSS) in a research report issued to clients and investors on Thursday. The brokerage set a “hold” rating on the stock.

Separately, Benchmark began coverage on shares of Milestone Scientific in a research note on Thursday, October 10th. They set a “speculative buy” rating and a $1.25 target price on the stock.

Milestone Scientific Price Performance

MLSS stock opened at $0.85 on Thursday. Milestone Scientific has a fifty-two week low of $0.52 and a fifty-two week high of $1.10. The firm’s 50-day simple moving average is $0.96 and its 200 day simple moving average is $0.81. The stock has a market cap of $65.66 million, a PE ratio of -8.50 and a beta of 1.08.

Milestone Scientific (NYSE:MLSS) last released its earnings results on Thursday, August 15th. The company reported ($0.02) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.01). The company had revenue of $1.85 million for the quarter. Milestone Scientific had a negative net margin of 54.87% and a negative return on equity of 60.78%.

Insider Buying and Selling at Milestone Scientific

In other Milestone Scientific news, Director Leonard Osser sold 141,913 shares of the firm’s stock in a transaction dated Wednesday, August 21st. The shares were sold at an average price of $0.95, for a total transaction of $134,817.35. Following the transaction, the director now owns 4,602,506 shares of the company’s stock, valued at approximately $4,372,380.70. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last 90 days, insiders have sold 143,122 shares of company stock valued at $136,026. Company insiders own 24.75% of the company’s stock.

Milestone Scientific Company Profile

Milestone Scientific Inc, a biomedical technology research and development company, patents, designs, develops, and commercializes diagnostic and therapeutic injection technologies, and devices for medical, dental, and cosmetic use in the United States, China, and internationally. The company operates through Dental and Medical segments.